EUVIMEDEUVIMED entdecken
Open Access

Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up

Stefano Severi, Ilaria Grassi, Alberto Bongiovanni, Silvia Nicolini, Irene Marini, Donatella Arpa, Nicoletta Ranallo, Irene Azzali, Valentina Di Iorio, Anna Sarnelli, Monti Manuela, Elena Amadori und 10 weitere

Journal of Nuclear Medicine · 2024-09 · 65 (9) · 1409-1415

DOI: 10.2967/jnumed.123.266956 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 14.08.2024. Verfasst von Stefano Severi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine and Radiometabolic Units, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy. Hauptthemen laut MEDLINE: Meningioma, Octreotide, Meningeal Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recurrence of meningiomas after surgery and radiotherapy deserves specific attention because of the lack of active third-line therapies. Somatostatin receptors are usually overexpressed on the cell membrane of meningiomas, and this has led the way to a radionuclide theranostic approach. Diagnoses with 68Ga-DOTA-octreotide and peptide receptor radionuclide therapy (PRRT) with 90Y/177Lu-DOTA-octreotide are currently possible options within experimental protocols or as compassionate use in small patient groups.

Methods

From October 2009 to October 2021, 42 meningioma patients with radiologic recurrence after standard therapies were treated with 90Y-DOTATOC (dosage of 1.1 or 5.5 GBq) or with 177Lu-DOTATATE (dosage of 3.7 or 5.5 GBq) in a mean of 4 cycles. All patients showed intense uptake at diagnostic 68Ga-DOTATOC PET/CT or in an 111In-octreotide scan.

Results

Of 42 patients treated, 5 patients received 90Y-DOTATOC with a cumulative activity of 11.1 GBq and 37 patients received 177Lu-DOTATATE with a cumulative activity of 22 GBq. The disease control rate was 57%. With a median follow-up of 63 mo, median progression-free survival was 16 mo, and median overall survival was 36 mo. Retreatment 177Lu-PRRT was performed in 6 patients with an administered median activity of 13 GBq in a mean of 5 cycles. With a 75.8-mo follow-up, median progression-free survival and overall survival were 6.5 and 17 mo, respectively. Only 1 patient discontinued the treatment because of grade 3 platelet toxicity. A rapidly transient grade 2 neutropenia was recorded in 1 retreated patient.

Conclusion

PRRT in patients with advanced meningiomas overexpressing somatostatin receptor 2 was active and well tolerated, showing a 57% disease control rate. Furthermore, PRRT could represent a potential retreatment option. Further studies, also in combination with other treatments, are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaOctreotideMeningeal NeoplasmsHumansMaleFemaleMiddle AgedAgedFollow-Up StudiesAdultTreatment OutcomeReceptors, PeptideReceptors, SomatostatinOrganometallic CompoundsAged, 80 and over

Stichwörter der Autor:innen

177Lumeningiomasoncologypeptide receptor radionuclide therapy

Substanzen

OctreotideReceptors, Peptidelutetium Lu 177 dotatateReceptors, SomatostatinOrganometallic Compounds90Y-octreotide, DOTA-Tyr(3)-

Autor:innen und Institutionen

  • Nuclear Medicine and Radiometabolic Units, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy.
  • Osteoncology and Rare Tumor Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy; dr.bongiovanni@gmail.com.
  • Radiotherapy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Emilia Romagna, Italy.
  • Osteoncology and Rare Tumor Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy.
  • Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Italy.
  • Oncological Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola, Emilia Romagna, Italy.

Zitieren

APA

Severi, S., Grassi, I., Bongiovanni, A., Nicolini, S., Marini, I., Arpa, D., Ranallo, N., Azzali, I., Di Iorio, V., Sarnelli, A., Manuela, M., Amadori, E., Fabbri, L., Bartolini, D., Tosatto, L., Di Meco, F., Gurrieri, L., Riva, N., Calabro, L., …, & Sansovini, M. (2024). Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up. Journal of Nuclear Medicine, 65(9), 1409-1415. https://doi.org/10.2967/jnumed.123.266956

Vancouver

Severi S, Grassi I, Bongiovanni A, Nicolini S, Marini I, Arpa D, et al. Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up. Journal of Nuclear Medicine. 2024;65(9):1409-1415. doi:10.2967/jnumed.123.266956

BibTeX
@article{Severi2024,
  author = {Severi, Stefano and Grassi, Ilaria and Bongiovanni, Alberto and Nicolini, Silvia and Marini, Irene and Arpa, Donatella and Ranallo, Nicoletta and Azzali, Irene and Di Iorio, Valentina and Sarnelli, Anna and Manuela, Monti and Amadori, Elena and Fabbri, Lucia and Bartolini, Daniela and Tosatto, Luigino and Di Meco, Francesco and Gurrieri, Lorena and Riva, Nada and Calabro, Luana and Matteucci, Federica and Paganelli, Giovanni and Sansovini, Maddalena},
  title = {Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  volume = {65},
  number = {9},
  pages = {1409--1415},
  doi = {10.2967/jnumed.123.266956}
}
Kostenlos starten →